Johnson & Johnson results beat estimates

Johnson & Johnson (JNJ) reported its latest financial results for the second quarter before the opening bell in the US on Tuesday.

The US pharmaceutical and consumer goods company reported revenue that topped the Wall Street expectations at $24.02 billion (up 3% year-over-year) vs. $23.771 billion expected.

Earnings per share reported at $2.59 per share (up 4.4% year-over-year) vs. $2.54 per share estimate.

”Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, CEO of the company.

”I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world,” Duato concluded.

Johnson & Johnson (JNJ) chart

The stock was down by around 1% during the trading day on Tuesday at $172.37 per share.

Here is how the stock has performed in the past year:

• 1 Month -0.31%
• 3 Month -5.79%
• Year-to-date +0.82%
• 1 Year +2.39%

Johnson & Johnson price targets

• Wells Fargo $195
• Morgan Stanley $174
• Citigroup $205
• Raymond James $196
• Credit Suisse $205
• Goldman Sachs $181

Johnson & Johnson is the 10^th largest company in the world with a market cap of $453.99 billion.

You can trade Johnson & Johnson (JNJ) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD.

Sources: Johnson & Johnson, TradingView, MetaTrader 5, Benzinga, CompaniesMarketCap